aurora a kinase/tyrosine kinase inhibitor enmd-2076
Generic: Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076
aurora a kinase/tyrosine kinase inhibitor enmd-2076: 1 clinical trial tracked.
aurora a kinase/tyrosine kinase inhibitor enmd-2076 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about aurora a kinase/tyrosine kinase inhibitor enmd-2076, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)
Primary endpoint: Overall Response Rate
Interventionalopen35 enrolledStarted 2015-10Completion 2018-065 sites · United StatesCASI Pharmaceuticals, Inc.